Library: Abstract and Posters

Abstracts and Posters

We would like to take this opportunity to thank all those who have participated in the various studies: their role is of great importance and does not always get the recognition it deserves.

Abstracts and posters arising from work carried out by the group are listed below. Please note that preliminary data may have been presented at meetings prior to publication of the final analysis.

Posters and presentations are provided in Adobe Acrobat (pdf) format.


2010	2009	2008	2007	2006
2005	2004	2003	2002	2001
2000	1999	1998

2010
	Pharmacogenetics - upcoming applications to patient care. Owen A. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010, abstract 113.
	Genetic variants of ABCC10 are associated with kidney tubular dysfunction in patients treated with tenofovir-containing regimens. Pushpakom S, Liptrott N, Rodríguez-Nóvoa S, Labarga P, Soriano V, Albalater M, Hopper-Borge E, Back D, Khoo S, and Owen A. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010, abstract 742.
	A population pharmacokinetic model illustrates an association between a pregnane-X-receptor (PXR) polymorphism and boosted atazanavir clearance. Schipani A, Siccardi M, Boffito M, D’Avolio A, Bonora S, Davies G, Khoo S, Back D, Di Perri G, and Owen A. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010, abstract 618.
	Raltegravir is a substrate for the influx transporters OAT1 and PEPT1 and the efflux transporter Pgp but is not transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2. Moss D, Kwan WS, Liptrott N, Siccardi M, Anstee D, Khoo S, Back D, and Owen A. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010, abstract 613.
	Integrating pharmacogenetics and population pharmacokinetic analysis: simulating the impact of CYP2B6 516G>T for 400 mg once daily nevirapine dosing. Schipani A, Mahungu T, Wyen C, Esser S, Brockmeyer N, Khoo S, Johnson M, Davies G, Owen A, and Back D. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010, abstract 601.
	Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Liptrott N, Pushpakom S, Wyen C, Rockstroh J, Mauss S, Knechten H, Brockmeyer N, Hopper-Borge E, Back D, Owen A, and German Competence Network for HIV/AIDS. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010, abstract 600.
	Solute carrier organic anion transporter 1B1 (SLCO1B1) mediates transport of maraviroc using a X. leavis model. Siccardi M, Moss D, Kwan WS, D’Avolio A, Bonora S, Khoo S, Back D, Di Perri G, and Owen A. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010, abstract 599.

2009
	A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance. Schipani A, Siccardi M, D'Avolio A, Baietto L, Calcagno A, Tettoni C, Bonora S, Davis G, Khoo S, Back DJ, Di Perri G, Owen A. 12th European AIDS Conference (EACS), Cologne, November 2009, abstract PE 4.1/7.
	Nevirapine hypersensitivity in Malawi: a prospective cohort study. Chaponda M, Ooosterhout J, Kumwenda J, Zijlstra E, White S, Lalloo D, Khoo S, Heyderman R, Pirmohamed M. 10th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, April 2009, abstract 0-20.
	Nevirapine drug exposure in drug-tolerant and hypersensitive Malawian patients. Chaponda M, Dickinson L, Davies G, Oosterhout J, Kumwenda J, White S, Lalloo D, Heyderman R, Pirmohamed M, Khoo S. 10th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, April 2009, abstract P-60.
	The prevalence of potential drug-drug interactions in the Swiss HIV Cohort Study. Gibbons S, Marzolini C, Elzi L, Khoo S, Ledergerber B, Back D, Battegay M, the Swiss HIV Cohort Study Members. 10th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, April 2009, abstract P-33.
	An exploratory analysis to determine the feasibility of raltegravir population pharmacokinetics in HIV-infected patients and healthy volunteers. Dickinson L, Back D, Watson V, Davies G, Aarons L, Khoo S, Jackson A, Boffito M. 10th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, April 2009, abstract P-10.
	Is maraviroc a substrate for SLCO1B1? Siccardi M, D’Avolio A, Nozza S, Bonora S, Castagna A, Baietto L, Stefani FR, Moss D, Calcagno A, Scinadra M, Lazzarin A, Back D, Owen A, Di Perri G. 10th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, April 2009, abstract P-02.
	Combined effect of SLCO1B1 521T>C, PXR 63396C>T, and ABCB1 3435C>T on the achievement of therapeutic concentrations of unboosted atazanavir. Siccardi M, D’Avolio A, Bonora S, Baietto L, Gatti D, Calcagno A, Ghisetti V, Lanzafame M, Penco G, Back D, Owen A, Di Perri G. 10th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, April 2009, abstract O-04.
	Prevalence of potential drug-drug interactions in the Swiss HIV Cohort Study. Marzolini C, Gibbons S, Elzi L, Khoo S, Ledergerber B, Battegay M, Back D. 15th Annual Conference of the British HIV Association, Liverpool, April 2009, abstract P141.
	Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected and healthy individuals. Dickinson L, Aarons L, Back D, Waters L, Else L, Khoo S, Pozniak A, Boffito M. 15th Annual Conference of the British HIV Association, Liverpool, April 2009, abstract P140.
	Population pharmacokinetics of nevirapine in HIV-infected adults. Schipani A, Wakeham K, Ggayi A, Kamali A, Lalloo DG, Youle M, Johnson M, Khoo S, Dickinson L, Back D. 15th Annual Conference of the British HIV Association, Liverpool, April 2009, abstract P139.
	Association between ABCB1 3435C>T and CYP2B6 516G>T and high-density lipoprotein cholesterol (HDL-c) changes in antiretroviral-naïve patients receiving first-line efavirenz-based regimens. Mahunga TW, Nair D, Smith CJ, Youle M, Johnson MA, Khoo SH, Back DJ, Owen A. 15th Annual Conference of the British HIV Association, Liverpool, April 2009, abstract P133.
	Nuclear receptor polymorphisms and boosted saquinavir plasma concentrations in HIV-infected subjects. Chaikan A, Egan D, Gibbons S, Khoo SH, Owen A, Back D. 15th Annual Conference of the British HIV Association, Liverpool, April 2009, abstract O23.
	Adipogenic gene variants in patients with HIV-associated lipodystrophy. Pushpakom S, Owen A, Vilar J, Back D, Pirmohamed M. 15th Annual Conference of the British HIV Association, Liverpool, April 2009, abstract O1.
	The genetic determinants of high-density lipoprotein cholesterol changes in HIV-1-infected adults on efavirenz-based regimens. Mahunga T, Nair D, Smith C, Turner F, Youle M, Johnson M, Egan D, Khoo S, Back D, Owen A. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, February 2009, abstract 716
	Predictors of kidney tubulopathy in HIV patients treated with tenofovir: a pharmacogentic study. Rodriguez Novoa S, Labarga P, Soriano V, Egan D, Morello J, Gonzalez-Pardo G, Cuenca L, Khoo S, Back D, Owen A. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, February 2009, abstract 37
	Coadministration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans. Wakeham K, Ggayi A-B, Watson V, Parkes R, Grosskurth H, Kamali A, Khoo S, Lalloo D. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, February 2009, abstract 700.

2008
	Validation of an ultra-sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for simultaneous determination of 11 anti-retroviral compounds Else L, Watson V, Tjia J, Siccardi M, Khoo S, Back D. British Pharmacology Society Winter Meeting, Brighton, December 2008, abstract CC005.
	Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected and healthy individuals. Dickinson L, Aarons L, Back D, Khoo S, Else L, Waters L, Pozniak A, Boffito M. British Pharmacology Society Winter Meeting, Brighton, December 2008, abstract CP036.
	Determining the substrate specificity of SLCO1B3 for antiretroviral drugs using a X. laevis model. Kwan WS, Moss D, Hartkoorn R, Salcedo-Sora E, Bray P, Khoo S, Back D, Owen A. British Pharmacology Society Winter Meeting, Brighton, December 2008, abstract P050.
	Drug interactions that really matter. Khoo SH. 9th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2008, abstract O121 (O123 in abstract book/CD).
	Prevalence of drug interactions between antiretroviral and co-administered drugs at the Moi Teaching and Referral Hospital (AMPATH), Eldoret-Kenya. Kigen G, Kimaiyo S, Owen A, Edwards G, Back D, Gibbons S, Sang E, Khoo S. 9th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2008, abstract O122 (O121 in abstract book/CD).
	An open-label multi-centre pilot study evaluating the pharmacokinetics of co-administered lopinavir and nevirapine in HIV-infected adults. The NRTI-sparing study. Else L, Mahungu T, Cuthbertson Z, Smith C, Podlekareva D, Hay P, Bak Dragsted U, Khoo S, Johnson M, Back D, Youle M. 9th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2008, abstract P250.
	Modelling the change in lopinavir apparent oral clearance over time following cessation of lopinavir/ritonavir: Data from the TAIL study. Dickinson L, Boffito M, Else L, Back D, Khoo S, Pozniak A, Moyle G, Aarons L. 9th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2008, abstract P241.
	Lopinavir is a substrate for SLCO1A2 but 516A>C and 38T>C polymorphisms do not influence lopinavir plasma concentrations. Shallcross V, Kwan WS, Hartkoorn R, Mahungu T, Khoo SH, Back DJ, Owen A. 9th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2008, abstract P238.
	Frequency of functional drug disposition gene polymorphism in Thai population: Relevance to antiretroviral drugs. Chaikan A, Chierakul N, Saguenwong N, Chuchuttaworn C, Owen A, Dickinson L, Khoo SH, Back DJ, Davies GR. 9th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2008, abstract P237.
	Plasma concentrations of boosted and unboosted atazanavir are predicted by 63396C>T SNP in the PXR gene. Siccardi M, D'Avolio A, Baietto L, Calcagno A, Gibbons SE, Sciandra M, Bonora S, Khoo SH, Back DJ, Di Perri G, Owen A. 9th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2008, abstract P233.
	A study to evaluate the efficacy, safety and tolerability of co-administered lopinavir/ritonavir and nevirapine in HIV-1 infected adults. The NRTI-sparing Study. Mahungu TW, Else LJ, Cuthbertson ZL, Smith CJ, Podlekareva D, Hay P, Dragsted UB, Johnson MA, Back DJ, Youle M. 9th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2008, abstract P006.
	Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and comedication. Stoehr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T, Schwenk J, Gazzard B. 9th International Workshop on Clinical Pharmacology of HIV Therapy, New Orleans, April 2008, Abstract O13.
	Total and unbound nevirapine pharmacokinetics in HIV-infected children treated with divided fixed-dose combination tablets in Malawi. Else LJ, Pollock L, Poerkson G, Back DJ, Khoo SH, Fraser W, Molyneux E. 9th International Workshop on Clinical Pharmacology of HIV Therapy, New Orleans, April 2008, Abstract O7.
	Determining the substrate specificities of SLCO1A2 and SLCO1B1 for antiretroviral drugs. Kwan WS, Hartkoorn RC, Salcedo-Sora JE, Bray P, Khoo S, Back DJ, Owen A. 9th International Workshop on Clinical Pharmacology of HIV Therapy, New Orleans, April 2008, Abstract O4.
	Influence of SLCO1B1 521T>C polymorphism on lopinavir plasma concentrations from the Liverpool TDM registry. Shallcross V, Hartkoorn R, Egan D, Kwan W, Khoo S, Back D, Owen A. 9th International Workshop on Clinical Pharmacology of HIV Therapy, New Orleans, April 2008, Abstract O3.
	The impact of CYP2B6 (516G>T, 1459C>T), CYP3A4 (-392A>G), CYP3A5 (6986A>G) and MDR1 (3435C>T, 2677G>T, 1236C>T) single nucleotide polymorphisms on the pharmacokinetics of nevirapine. Mahungu TW, Smith C, Turner F, Egan D, Youle M, Johnson MA, Khoo S, Back D, Owen A. 9th International Workshop on Clinical Pharmacology of HIV Therapy, New Orleans, April 2008, Abstract O1.
	No influence of single nucleotide polymorphisms in MDR1 (C3435T/G2677T) on the pharmacokinetics of lopinavir in Serbian patients. Dragovic G, Youle M, Back D, Smith C, Grbovic L, Jevtovic D, Owen A. 9th International Workshop on Clinical Pharmacology of HIV Therapy, New Orleans, April 2008, Abstract P2.
	Interferon-gamma genotype (874T>A) is associated with CCR5 expression in HIV+ patients. Liptrott N, Chandler B, Khoo S, Back D, Owen A. 15th Conference on Retroviruses and Opportunistic Infections, Boston, February 2008, abstract 297.
	A factorial study of the effect of HIV, TB, and pharmacogenetics on the pharmacokinetics and pharmacodynamics of anti-TB drugs. Davies G, Cheirakul N, Saguenwong N, Chaiprasert A, Chuchuttaworn C, Eompokalap B, Likanonsakul S, White N, Back D, Khoo S. 15th Conference on Retroviruses and Opportunistic Infections, Boston, February 2008, abstract 1005.

2007
	Prediction of once daily boosted protease inhibitor pharmacokinetic profiles based on twice daily concentration data. Dickinson L, Back D, Khoo S, Boffito M, Pozniak A, Davis J, Aarons L. 11th European AIDS Conference, Madrid, October 2007, abstract P4.1/02.
	Cytochrome P450 2B6 (CYP2B6) T983C homozygosity and influence upon NNRTI plasma concentrations in HIV-infected patients. Wyen C, Hendra H, Groneuer C, Vogel M, Hoffmann C, Knechten H, Brockmeyer N, Bogner J, Rockstroh J, Esser S, Jäger H, Harrer T, Mauss S, Skoetz N, Jetter A, Fätkenheuer G, Khoo SH, Egan D, Back D, Owen A, and the German Competence Network for HIV/AIDS. 11th European AIDS Conference, Madrid, October 2007, abstract P4.4/01
	Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice daily and once daily over 72 hours following drug intake cessation. Boffito M, Else L, Back D, Taylor J, Khoo S, Sousa M, Pozniak A, Gazzard B, Moyle G. 11th European AIDS Conference, Madrid, October 2007, abstract LBPS 7/4.
	Variability in lopinavir concentrations in the clinical setting and factors affecting concentrations. Gibbons S, Back D, Khoo S. 8th International Workshop on Clinical Pharmacology of HIV Infection, Budapest, April 2007, abstract 37.
	A simple pharmacokinetic analysis to assess the forgiveness for late dosing of boosted saquinavir regimens. Dickinson L, Back D, Khoo S, Shutz M, Boffito M. 8th International Workshop on Clinical Pharmacology of HIV Infection, Budapest, April 2007, abstract 14
	Total and unbound lopinavir pharmacokinetics during pregnancy and at delivery in HIV-infected women. Else L, Dickinson L, Bell C, Douglas M, Back D, Khoo S, Taylor G. 8th International Workshop on Clinical Pharmacology of HIV Infection, Budapest, April 2007, abstract 10
	TB drug tolerance: differential drug susceptibility of intracellular and extracellular TB and the effect of time of drug exposure. Hartkoorn R, Chandler B, Owen A, Ward S, Squire B, Back D, Khoo S. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 2007, abstract 854.
	Influence of PD1 genotype on virological and immunological response in patients initiating ART. Liptrott N, Mahungu T, Youle M, Johnson M, Smith C, Back D, Khoo S, Owen A. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 2007, abstract 452.
	Abacavir plasma pharmacokinetics in the absence and the presence of atazanavir/ritonavir or lopinavir/ritonavir) and vice versa in HIV+ patients. Waters L, Moyle G, D’Avolio A, Sciandra M, ElseL, Pozniak A, Nelson M, Gazzard B, Back D, Boffito M. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 2007, abstract 557.
	The assessment of multi-locus gene effects upon efavirenz pharmacokinetics. Mahungu T, Khoo S, Smith C, Youle M, Johnson M, Back D, Owen A. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 2007, abstract 552.

2006
	Use of TMC114 in combination with other drugs: guidance from pharmacokinetic studies. Back D, Sekar V, Lefebvre E, De Pauw M, De Paepe E, Vangeneugden T, Hoetelmans R. 8th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2006, abstract PL5.1.
	The assessment of multi-locus gene effects upon lopinavir pharmacokinetics. Owen A, Mahungu T, Cook C, Youle M, Johnson M, Back D, Khoo S. 8th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2006, abstract PL5.4.
	Therapeutic drug monitoring (TDM): is it of clinical utility in HIV+ pregnant women? Caswell RJ, Doshi S, Khoo SH, Chaponda M, Poulton M, Welch J, Gibbons S, McDonald C, Lambert JS. 8th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2006, abstract P379.
	Pharmacokinetics (PK), safety, tolerability and efficacy of boosted saquianvir 500 mg film coated tablets in a regimen of 1000/100 mg bid plus 2 nucleoside analogues (NRTIs) in HIV+ pregnant women. Tung MY, Boffito M, Taylor S, Short M, Gibbons S, Back D, Khan W, Hawkins SA. 8th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2006, abstract P383.
	Trough concentrations in HIV patients receiving boosted hard-gel capsules (HGC) and 500 mg film-coated tablet (FCT) formulations of saquinavir. Dickinson L, Back D, Winston A, Khoo S, Boffito M. 8th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2006, abstract P271.
	Exploring the feasibility of dried blood spots for quantification of lopinavir, nevirapine and efavirenz concentrations. Else LJ, Dickinson L, Schellenberger M, Khoo S, Back D. 8th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2006, abstract P272.
	Approaches to the analysis of therapeutic drug monitoring data. Gibbons S, Back D, Boffito M, Youle M, Khoo S. 8th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2006, abstract P273.
	Interactions between efavirenz and cellular efflux transporters. Chandler B, Holmes B, Janneh O, Kwan WS, Owen A, Khoo SH, Back DJ. XVI International AIDS Conference, Toronto, August 2006, abstract TUPE0095.
	The steady state pharmacokinetics of lopinavir/ritonavir 533/133 mg bid plus nevirapine (200 mg bid) in adult HIV-1 infected individuals (the NRTI sparing study). Youle M, Else L, Cuthbertson Z, Khoo S, Back D. XVI International AIDS Conference, Toronto, August 2006, abstract TUPE0094.
	An audit of TDM in paediatric subjects in United Kingdom clinics, 1999-2005. Gibbons S, Cliff D, Back D, Khoo S. XVI International AIDS Conference, Toronto, August 2006, abstract TUPE0093.
	Plasma levels of nevirapine following interruption of ZDV/3TC /NVP in African adults within the DART trial. Kikaire B, Walker S, Khoo S, Munderi P, Ssali F, Namale L, Reid A, Gibb D, Mugyenyi P, Grosskurth H. XVI International AIDS Conference, Toronto, August 2006, abstract WEAB0201.
	Pharmacokinetic and virological evaluations after stopping NNRTIs in children: a substudy of the PENTA 11 (TICCH) trial. Lallemant M, Burger D, Lyall H, Buck L, Compagnucci A, Ramos Amador JT, Mellado Pena MJ, Fregonese F, Campbell S, Rampon O, Castelli-Gattinara G, Cressey T, Khoo S, Tréluyer J-M, Green H, Saidi Y, Nadal D, Giaquinto C, Gibb DM, on behalf of PENTA. XVI International AIDS Conference, Toronto, August 2006, abstract MOPE0206.
	The impact of cytokines on the expression of HIV relevant membrane bound proteins. Liptrott, NJ, Back DJ, Penny M, Khoo SH, Owen A. 9th European ISSX Meeting, Manchester, June 2006.
	Influence of drug efflux transporters on cellular accumulation of darunavir (TMC114). Kwan WS, Chandler B, Holmes R, Hoetelmans R, Sekar V, Owen A, Khoo S, Dack D. 7th International Workshop on Clinical Pharmacology of HIV Therapy, Lisbon, April 2006, Abstract 61.
	The pharmacokinetics of lopinavir/ritonavir (533/133 mg b.i.d.) plus nevirapine (200 mg b.i.d.) in adult HIV-1 infected individuals. Else L, Cuthbertson Z, Khoo S, Johnson M, Back D, Youle M. 7th International Workshop on Clinical Pharmacology of HIV Therapy, Lisbon, April 2006, Abstract 67.
	Intra-patient variability and comparison of saquinavir/ritonavir Ctrough concentrations between HIV-infected individuals and healthy volunteers administered saquinavir mesylate 500 mg film-coated tablets (1000/100 mg twice daily). Dickinson L, Back D, Winston A, Khoo S, Boffito M. 7th International Workshop on Clinical Pharmacology of HIV Therapy, Lisbon, April 2006, Abstract 60.
	An audit of TDM in paediatric subjects from the UK and Ireland. Gibbons S, Back D, Khoo S. 7th International Workshop on Clinical Pharmacology of HIV Therapy, Lisbon, April 2006, Abstract 8.
	The assessment of muli-locus gene effects upon nevirapine pharmacokinetics. Owen A, Cook C, Youle M, Back D, Khoo S. 7th International Workshop on Clinical Pharmacology of HIV Therapy, Lisbon, April 2006, Abstract 31.
	Induction of ART-relevant drug transporters and metabolism enzymes in intestinal and hepatic cells by rifampicin. Martin P, Riley R, Khoo S, Back D, Owen A. 13th Conference on Retroviruses and Opportunistic Infections, Denver, February 2006, abstract 567.
	Relationship of G516T polymorphism to lymphocyte expression of CYP2B6. Owen A, Cook C, Liptrott N, Khoo S, Back D. 13th Conference on Retroviruses and Opportunistic Infections, Denver, February 2006, abstract 765.

2005
	Is once-daily dosing of PIs associated with decreased tolerance for missed or late doses? Gibbons S, Dickinson L, Boffito M, Pozniak A, Back D, Khoo S. 10th European Aids Conference, Dublin, November 2005, poster PE 4.1/8.
	Limited sampling strategy analysis to predict AUC of twice-daily boosted saquinavir (1000/100mg bid). Dickinson L, Back D, Pozniak A, Khoo A, Boffito M. 10th European AIDS Conference, Dublin, November 2005, poster PE4.1/9
	Is there evidence of age-dependent variation in lopinavir or efavirenz levels in female subjects in the clinical setting? Gibbons SE, Back DJ, Khoo SH. 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec, April 2005, poster 4.8.
	A retrospective survey of the Liverpool TDM Service: factors influencing efavirenz concentrations in patients taking rifampicin. Almond L, Gibbons S, Davies G, Dack D, Khoo S. 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec, April 2005, poster 2.12.
	The effect of proton pump inhibitors on protease inhibitor plasma concentrations in the clinical setting. Gibbons SE, Back DJ, Khoo SH. 11th Annual Conference of the British HIV Association with the British Association for Sexual Health and HIV, Dublin, April 2005, abstract P29.
	Efavirenz concentrations resulting from co-administration of rifampicin with either 600 or 800 mg efavirenz. Gibbons S, Almond L, Back D, Khoo S. 11th Annual Conference of the British HIV Association with the British Association for Sexual Health and HIV, Dublin, April 2005, abstract P33.
	P-glycoprotein and MRP1 interactions with rifampicin. Hartkoorn R, Waitt C, Chaponda M, Davies G, Chandler B, Owen A, Ward S, Back D, and Khoo S. 12th Conference on Retroviruses and Opportunistic Infections, Boston, February 2005, abstract 666.

2004
	Correlation between transporters and HIV co-receptors in lymphocytes from HIV-infected patients: superimposition of host genotype. Owen A, Chandler B, Walsh T, Williams J, Penny M, Back D, Khoo S. Presented at the 2004 Meeting on Pharmacogenomics, Cold Spring Harbor, November 2004.
	Intracellular and plasma pharmacokinetics of saquinavir, atazanavir and ritonavir 1600/200/100 mg administered once daily in HIV infected patients. Ford J, Boffito M, Wildfire A, Hill A, Back D, Khoo S, Nelson M, Moyle G, Gazzard B, Pozniak A. 7th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2004, abstract PL6.3b.
	Effect of atazanavir on intracellular and plasma pharmacokinetics of saquinavir and ritonavir administered once daily in HIV infected patients. Ford J, Boffito M, Wildfire A, Hill A, Khoo S, Nelson M, Moyle G, Gazzard B, Pozniak A, Back D. 7th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2004, abstract PL6.3a.
	Higher nevirapine doses correlate with improved outcomes in a paediatric population. Alexanian A, Gibbons S, Lyall EGH, Walters S, Khoo S, Tudor-Williams G. 7th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2004, abstract PL 11.2.
	Pharmacokinetics of saquinavir hard gel / ritonavir in combination with differenent doses of atazanavir once daily in HIV+ patients. Boffito M, Maitland D, Dickinson L, Back D, Hill A, Moyle G, Nelson M, Fletcher C, Gazzard B, Pozniak A. 7th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2004, abstract P272.
	The pharmacokinetics of saquinavir and ritonavir in Ugandan patients receiving ritonavir boosted saquinavir hard gel and soft gel. Coakely P, Merry C, Kityo C, Ryan M, Mugyenyi P, Back D, Gibbons S, Lange JMA. 7th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2004, abstract P277.
	Therapeutic drug monitoring of atazanavir in routine clinical settings in the UK. Gibbons S, Robinson L, Dickinson L, Tjia J, Robertson A, Stainsby-Tron M, Kewn S, Back D, Khoo S. 7th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2004, abstract P274.
	Intracellular and unbound concentrations of efavirenz and nevirapine in vivo. Almond LM, Boffito M, Dalton M, Edirisinghe D, Bonington A, Back DJ, Khoo S. 7th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2004, abstract P278.
	Detection of minority strains of HIV harbouring drug resistance. Detsika MG, Winstanley C, Owen A, Cane P, Khoo SH, Back DJ, Hart CA. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, October/November 2004, abstract H-193
	Effects of individual and combinations of antiretrovirals on adipocyte function and viability Janneh O, Spiller DG, White MRH, Back DJ, Pirmohamed M. XVth International AIDS Conference, Bangkok, July 2004, abstract WePeB5890.
	Importance of multidrug resistance protein and P-glycoprotein in the intracellular accumulation of saquinavir: Effects of specific inhibitors. Janneh O, Back DJ, Khoo SH. XVth International AIDS Conference, Bangkok, July 2004, abstract TuPpA2033.
	Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine and zidovudine containing regimens. Jones SP, Qazi N, Walker UA, Moyle G, Back DJ, Pirmohamed M. XVth International AIDS Conference, Bangkok, July 2004, abstract WePeB5948.
	Co-expression and co-localisation of P-glycoprotein and CXCR4 in peripheral blood mononuclear cells. Chandler B, Owen A, Bray PG, Ward SA, Back DJ, Khoo SH. XVth International AIDS Conference, Bangkok, July 2004, abstract TuPeB4614.
	Tenofovir (TDF) does not alter the pharmacokinetics (PK) of saquinavir hard gel capsule (SQV-hgc)/ritonavir (RTV): data from HIV+ patients. Boffito M, Back D, Stainsby-Tron M, Hill A, Di Perri G, Moyle G, Nelson M, Higgs C, Fletcher C, Gazzard B, Pozniak A. XVth International AIDS Conference, Bangkok, July 2004, abstract TuPeB4610.
	In vitro interaction between mefloquine and saquinavir: The role of breast cancer resistance protein. Owen A, Janneh O, Bray PG, Ward SA, Baba M, Back DJ, Khoo SH. XVth International AIDS Conference, Bangkok, July 2004, abstract TuPeB4588.
	Is there evidence for weight-adjusted dosing of Kaletra? Gibbons S, Robinson L, Davies G, Back DJ, Khoo SH. 10th Anniversary Conference of the British HIV Association, Cardiff, April 2004, abstract P75.
	Protease inhibitor accumulation in lymphocytes in vivo and lymphocyte subsets in vitro with P-glycoprotein expression. Ford J, Boffito M, Hill A, Hoggard PG, Khoo SH, Pozniak A, Back DJ. 5th International Workshop on Clinical Pharmacology of HIV Therapy, Rome, April 2004, abstract 51 (poster 6.8).
	Pharmacokinetics of saquinavir hard gel/ritonavir with atazanavir or fosamprenavir in HIV+ patients. Boffito M, Back D, Kurowski M, Dickinson L, Kruse G, Hill A, Moyle G, Nelson M, Higgs C, Fletcher C, Gazzard B, Pozniak A. 5th International Workshop on Clinical Pharmacology of HIV Therapy, Rome, April 2004, abstract 17 (poster 4.5)
	Repeated pharmacokinetics of tenofovir disoproxil fumarate in HIV-infected adults receiving saquinavir/ritonavir 1000/100 mg bid. Boffito M, D'Avolio A, Di Perri G, Sciandra M, Bonora S, Back D, Hill A, Moyle G, Nelson M, Higgs C, Tomkins J, Gazzard B, Pozniak A. 5th International Workshop on Clinical Pharmacology of HIV Therapy, Rome, April 2004, abstract 31 (poster 4.19).
	Saquinavir hard gel/ritonavir pharmacokinetics: effect of high fat meals, plasma concentration diurnal variation and intrapatient variability. Boffito M, Back D, Dickinson L, Hill A, Moyle G, Nelson M, Higgs C, Fletcher C, Gazzard B, Pozniak A. 5th International Workshop on Clinical Pharmacology of HIV Therapy, Rome, April 2004, abstract 65 (poster 7.6).
	Steady state pharmacokinetics of saquinavir hard gel/fosamprenavir 1000/700 plus 100 mg and 200 mg of ritonavir twice daily in HIV+ patients. Boffito M, Dickinson L, Hill A, Nelson M, Moyle G, Higgs C, Fletcher C, Mandalial S, Back D, Gazzard B, Pozniak A. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2004, abstract 608
	Intracellular and plasma pharmacokinetics of saquinavir/ritonavir administered once daily in HIV infected patients. Ford J, Boffito M, Wildfire A, Hill A, Back D, Khoo S, Nelson M, Moyle G, Gazzard G, Pozniak A. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2004, abstract 601.
	Relationships between p-glycoprotein, CXCR4 expression and saquinavir antiviral effect in vitro. Chandler B, Owen A, Back D, Khoo S. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2004, abstract 618
	The role of genetic polymorphisms of the MDR1 gene in the MaxCmin1 study. Owen A, Fox Z, Almond L, Bak Dragsted U, Back D, Youle M, Lundgren J, Khoo S, the MaxCmin1 Steering Committee. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2004, abstract 619b.
	Effect of NRTI and PI on TNF-alpha and adiponectin mRNA expression in isolated subcutaneous and omental mature human adipocytes. Jones SP, Waitt CJ, Back DJ, Pirmohamed M. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2004, abstract 707

2003
	Therapuetic drug monitoring: lessons from four years of running a clinical service in the UK Gibbons SE, Robinson L, Tjia JF, Back DJ, Khoo SH. 9th European AIDS Conference, Warsaw, October 2003, abstract 4.2/7.
	Intra-individual variability in nevirapine plasma concentrations. Almond LM, Boffito M, Hoggard PG, Bonora S, Raiteri R, Sinnico A, Di Perri G, Back DJ 9th European AIDS Conference, Warsaw, October 2003, abstract 4.2/3.
	The relationship between intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV infected patients with P-glycoprotein expression. Ford J, Hoggard PG, Meaden ER, Newton P, Cuthbertson Z, Williams I, Johnson M, Daniels E, Hsyu P, Khoo SH, Back DJ. 9th European AIDS Conference, Warsaw, October 2003, abstract F2/2..
	Efavirenz, rifampicin and rifabutin - a case for therapeutic drug monitoring? Lewthwaite P, Gibbons S, Vilar FJ, Khoo SH. 2nd IAS Conference on Pathogenesis and Treatment, Paris, July 2003, abstract 851. Antiviral Ther, 2003, Suppl 1:S424.
	The inhibitory effects of the HIV protease inhibitors and HIV-1 on P-glycoprotein in vitro. Chandler B & Back D. 2nd IAS Conference on Pathogenesis and Treatment, Paris, July 2003, abstract 871 Antiviral Ther, 2003, Suppl 1: S429-430.
	Altered adipocytokine gene expression in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors. Jones SP, Janneh O, Back DJ, Pirmohamed M. 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Paris, July 2003, abstract 11. Antiviral Ther, 2003, 8:L11
	Mode of uptake, accumulation and intracellular disposition ofzidovudine in cultured 3T3-F442A preadipocytes. Janneh O, Bray PG, Owen A, Back DJ, Pirmohamed M. 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Paris, July 2003, abstract 28. Antiviral Ther, 2003, 8: L24-L25
	A pilot survey of opinions amongst HIV nurses to discuss the need for palliative care within HIV nursing. Dalton M & Dantith R. 5th National HIV Nurses Association Conference, Brighton, June 2003.
	Lipodystrophy and altered body image. Dalton M & Jones SP. 5th National HIV Nurses Association Conference, Brighton, June 2003.
	Pharmacological optimisation of PIs and NNRTIs (POPIN): case studies of four patients receiving a nurse led TDM/adherence package. Dalton M, Reynolds H, Lloyd J, Gibbons S, Bonnington A, Wilkins E, Sweeney J, Flegg P, Back DJ, Khoo SH. 5th National HIV Nurses Association Conference, Brighton, June 2003
	The relationship between P-glycoprotein and HIV-1 co-receptor expression: implications for antiretroviral disposition and viral dynamics. Owen A, Chandler B, Khoo SH, Back DJ. 8th European Meeting of the International Society for the Study of Xenobiotics, Dijon, April 2003, abstract 307
	Factors influencing nevirapine plasma concentrations. Gibbons SE, Almond L, Reynolds H, Dickinson L, Robinson L, Khoo SH, Boffito M, Bonora S, Di Perri G, Back DJ. 9th Annual Conference of the British HIV Association, Manchester, April 2003, Abstract P3. HIV Med, 2003, 4:209
	Relationship between nevirapine plasma concentration and abnormal liver function tests in a cohort of heterogeneous HIV+ patients Almond L, Boffito M, Hoggard P, Bonora S, Raiteri R, Reynolds H, Khoo S, Di Perri G, Back D. 4th International Workshop on Clinical Pharmacology of HIV Infection, Cannes, March 2003, abstract 4.3.
	The effect of antiretroviral protease inhibitors on P-gp expression in CD4 and CD8 subpopulations of lymphocytes. Ford J, Chandler B, Khoo SH, Back DJ 4th International Workshop on Clinical Pharmacology of HIV Therapy, Cannes, March 2003, abstract 2.2.
	Mycophenolate mofetil lowers plasma nevirapine concentrations but has no effect on intracellular triphosphate concentrations. Sankatsing S, Hoggard P, Back S, Kewn S, Huitema A, Crommentuyn K, Beijnen J, Lange J, Prins J. 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 2003, abstract 539
	Relationship between P-glycoprotein and HIV-1 receptors in peripheral blood lymphocytes and cell lines Owen A, Hoggard PG, Chandler B, Khoo SH, Back DJ. 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 2003, abstract 149
	The effect of ABCB1 (MDR1) polymorphism on the plasma and intracellular pharmacokinetics of indinavir and glucose handling in healthy volunteers. Maher B, Hoggard PG, Chandler B, Meaden ER, Owen A, Back DJ, Khoo SH, Pirmohamed M. 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 2003, abstract 524a
	Lopinavir/ritonavir combined with twice-daily indinavir: pharmacokinetics in blood, CSF and semen (The Protect Study) Isaac A, Taylor S, Rubin G, Gibbons S, White D, Drake S, Back D. 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 2003, abstract 531

2002
	The intracellular accumulation of lopinavir (LPV) and ritonavir (RTV) is influenced by the expression of efflux transporters P-glycoprotein and MRP1 in HIV infected patients receiving Kaletra. Hoggard P, Meaden E, Newton P, Williams I, Tjia J, Cornforth D, Aldam D, Back D, Khoo S. 6th International Congress on Drug Therapy in HIV Infection, Glasgow, October 2002, abstract PL8.2.
	The effect of protease inhibitor containing regimens on multidrug resistance transporter expression. Ford J, Meaden R, Hoggard P, Khoo S, Back D. 6th International Congress on Drug Therapy in HIV Infection, Glasgow, October 2002, abstract PL8.2.
	In-vitro antiretroviral activity of antimalarial agents. Owen A, Hoggard P, Bray P, Ward S, Khoo S, Hart A, Back D. 6th International Congress on Drug Therapy in HIV Infection, Glasgow, October 2002, abstract P64.
	Lopinavir concentrations in children. Lyall H, Head S, Gibbons S, Khoo S. 6th International Congress on Drug Therapy in HIV Infection, Glasgow, October 2002, abstract P76.
	Efavirenz (EFV) concentrations in children. Lyall H, Head S, Gibbons S, Khoo S. 6th International Congress on Drug Therapy in HIV Infection, Glasgow, October 2002, abstract P77.
	Effects of protease inhibitors and nucleoside reverse transcriptase inhibitors onadipogenesis, cell viability, lipolysis and TNF-alpha release in Murine 3T3-L1 cells. Janneh O, Hoggard PG, Sales SD, Jones SP, Tjia JF, Khoo SH, Maher B, Back DJ, Pirmohamed M. 6th International Congress on Drug Therapy in HIV Infection, Glasgow, October 2002, abstract P137.
	Nevirapine protein binding in HIV infected individuals. Almond L, Boffito M, Hoggard P, Bonora S, Raiteri R, Sinicco A, Di Perri G, Back D. 6th International Congress on Drug Therapy in HIV Infection, Glasgow, October 2002, abstract P164.
	The use of therapeutic drug monitoring (TDM) in the management of HAART-related toxicity. Forsyth S, French P, Macfarlane E, Gibbons S. 6th International Congress on Drug Therapy in HIV Infection, Glasgow, October 2002, abstract P174.
	Five case reports advocating the use of therapeutic drug monitoring of lopinavir/ritonavir. Boffito M, Bonora S, Lucchini A, Maiello A, Dal Conte I, Khoo S, Back DJ, Di Perri G. 6th International Congress on Drug Therapy in HIV Infection, Glasgow, October 2002, abstract P184.
	Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring. Boffito M, Bonora S, Hoggard PG, Reynolds HE, Sinicco A, Back DJ, Di Perri G. 6th International Congress on Drug Therapy in HIV Infection, Glasgow, October 2002, abstract P185.
	Therapeutic drug monitoring of NNRTIs in patients with hepatic dysfunction. Gibbons S, Taylor C, Waldron S, Back DJ, Weber J, Khoo SH. 6th International Congress on Drug Therapy in HIV Infection, Glasgow, October 2002, abstract P174.
	Effect of efavirenz and nevirapine on P-gp expression: the impact on protease inhibitor fluxing. Almond LM, Chandler B, Hoggard PG, Owen A, Khoo SH, Back DJ. 14th World AIDS Conference, Barcelona, July 2002, abstract TuPeB4569.
	Induction of P-glycoprotein in PBMCs in vitro. Chandler B, Ford J, Owen A, Khoo SH, Back DJ 14th World AIDS Conference, Barcelona, July 2002, abstract TuPeB4551.
	Development of an enzymatic assay for the quantification of intracellular (-)-beta-d-1,3-dioxolane guanosine triphosphate levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients. Kewn S, Wang LH, Rousseau F, Hoggard PG, Back DJ. 14th World AIDS Conference, Barcelona, July 2002, abstract TuPeB4544.
	The pharmacokinetic interaction of lopinavir/ritonavir and amprenavir in clinical practice. Reynolds HE, Gibbons SE, Tjia JF, Khoo SH, Back DJ. 14th World AIDS Conference, Barcelona, July 2002, abstract TuPeB4560.
	Pharmacoenhancement of saquinavir by cimetidine: an alternative booster to ritonavir? Boffito M, Trentini L, Raiteri R, Bonora S, Sinicco A, Reynolds HE, Hoggard PG, Back DJ, Di Perri G. 3rd International Workshop on Clinical Pharmacology of HIV Therapy, Washington, April 2002, abstract 2.8
	Pharmacokinetics and pharmacodynamics of lopinavir in a salvage therapy setting. Boffito M, Arnaudo I, Raiteri R, Bonora S, Sinicco A, Reynolds HE, Hoggard PG, Back DJ, Di Perri G. 3rd International Workshop on Clinical Pharmacology of HIV Therapy, Washington, April 2002, abstract 3.1
	Intracellular accumulation of lopinavir and ritonavir in HIV patients receiving Kaletra. Hoggard PG, Meaden ER, Newton P, Williams I, Tjia JF, Aldam D, Cornforth D, Back DJ, Khoo SH. 3rd International Workshop on Clinical Pharmacology of HIV Therapy, Washington, April 2002, abstract 5.2.
	POPIN: The implementation of a nurse-led TDM/adherence package for patients receiving HAART. Lloyd J, Sweeney J, Flegg P, Bonington A, Wilkins E, Gibbons S, Back D, Khoo S. 8th Annual Conference of the British HIV Association, York, April 2002, abstract P29. HIV Med, 2002, 3: 181
	The clinical utility of TDM in the management of patients receiving indinavir and ritonavir. Gibbons SE, Reynolds HE, Lloyd JL, Tjia JF, Khoo SH, Back DJ. 8th Annual Conference of the British HIV Association, York, April 2002, abstract P28. HIV Med, 2002, 3: 180.
	The pharmacokinetic interactions of lopinavir/ritonavir (LPV/r) and amprenavir (APV) in clinical practice. Gibbons SE, Reynolds HE, Tjia JF, Lloyd JL, Khoo SH & Back DJ. 8th Annual Conference of the British HIV Association, York, April 2002, abstract P27. HIV Med, 2002, 3: 180-181.
	Efavirenz and nevirapine – possible candidates for therapeutic drug monitoring in clinical practice? Gibbons SE, Reynolds HE, Lloyd JL, Tjia JF, Khoo SH, Back DJ. 8th Annual Conference of the British HIV Association, York, April 2002, abstract O17. HIV Med, 2002, 3: 163-164
	Pharmacokinetics and genotyping in Lopinavir recipients with prior PI failure Boffito M, Arnaudo I, Bonora S, Sinicco A, Raiteri R, Hoggard P, Back D, Di Perri G. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, February 2002, abstract 453-W.
	Virological failure is associated with decreased 3TC triphosphate (3TCTP) and ratio of 3TCTP/endogenous deoxycytidine triphosphate in HIV-infected individuals in a clinical setting. Hoggard P, Kewn S, Lloyd J, Sales S, Wilkins S, Maher B, Meaden E, Almond L, Jones T, Pillay D, Sabin C, Khoo S, Back D. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, February 2002, abstract 455-W.
	Reduced accumulation of ritonavir and saquinavir in PBMCs in vivo is associated with increased P-gp and MRP1 expression in HIV-infected individuals. Meaden E, Hoggard P, Newton P, Tjia JF, Aldam D, Cornforth D, Lloyd J, Smith A, Williams I, Beeching N, Stockwell E, Wilkins E, Carey P, Back D, Khoo S. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, February 2002, abstract 127.

2001
	CHARM phosphorylation substudy – Effect of hydroxyurea on nucleoside analogue and endogenous nucleoside triphosphates. Hoggard P, Kewn S, Almond L, Maherbe A, Sales S, De Vries C, Gould J, Yu Lou, Wood R, Khoo S, Back D. 8th European Conference on Clinical Aspects and Treatment of HIV Infection, Athens, October 2001, abstract P158.
	Intracellular accumulation of the protease inhibitors saquinavir (SQV) and indinavir (IDV) – The effect of co-administration with ritonavir (RTV). Khoo SH, Hoggard PG, Meaden ER, Smith A, Williams I, Lloyd J, Tija J, Reynolds H, Wilkins EGL, Beeching NJ, Peters B, Back DJ. 8th European Conference on Clinical Aspects and Treatment of HIV Infection, Athens, October 2001, abstract P159.
	HIV infection and the degree of virological suppression: impact on P-gp and MRP expression. Meaden ER, Hoggard PG, Khoo SH, Lloyd J, Williams I, Newton P, Wilkins EG, Back DJ. 8th European Conference on Clinical Aspects and Treatment of HIV Infection, Athens, October 2001, abstract P161
	Therapeutic drug monitoring of anti-HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors: a report on the Liverpool TDM service. Gibbons SE, Reynolds HE, Lloyd J, Tjia J, Khoo S, Back DJ. British Pharmacological Society, Dublin, July 2001, abstract P122.
	Expression of the efflux transporters P-gp and MRP in Caucasian and black African healthy volunteers and HIV-infected Caucasians. Meaden ER, Hoggard PG, Chandler B, Khoo SH, Back DJ. British Pharmacological Society, Dublin, July 2001, abstract P123
	Intracellular drug/endogenous nucleoside triphosphate ratios in HIV infected patients on lamivudine and abacavir as part of combination therapy (Malibu Study). Hoggard PG, Kewn S, Lloyd J, Sales S, Almond L, Meaden ER, Jones T, Wilkins D, Sabin C, Pillay D, Khoo SH, Back DJ. British Pharmacological Society, Dublin, July 2001, abstract C77.
	Opiate withdrawal syndrome in new efavirenz recipients under methadone maintenance regimen. Boffito M, Rossati A, Dal Conte I, Reynolds H, Gibbons S, Back D, Di Perri G. 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, July 2001, abstract 340.
	Indinavir and saquinavir unbound fraction measurements in HIV-1 positive patient plasma. Boffito M, Tjia J, Reynolds H, Hoggard P, Meaden E, Di Perri C, Back D. 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, July 2001, abstract 343.
	Simultaneous determination of four HIV protease inhibitors by HPLC-MS/MS for use in the therapeutic drug monitoring service. Reynolds HE, Tjia JF, Gibbons SE, Khoo SH, Back DJ. British Pharmacological Society, Dublin, July 2001, abstract P124.
	Penetration of non-nucleoside reverse transcriptase inhibitors (NNRTIs) into the male genital tract: variable drug concentrations in semen and blood plasma of HIV-1 infected men. Taylor S, Reynolds H, Sabin C, Drake S, White D, Back D, Pillay D. 2nd International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, April 2001, abstract 2.2.
	Protein binding of saquinavir alone and in combination with ritonavir. Boffito M, Tjia J, Reynolds HE, Hoggard PG, Meaden ER, Khoo S, Di Perri G, Back DJ. 2nd International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, April 2001, abstract 8.2.
	Variation in expression of the multidrug resistance transporters P-gp and MRP with ethnicity and HIV infection. Meaden ER, Chandler B, Hoggard PG, Khoo SH, Back DJ. 2nd International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, April 2001, abstract 2.4.
	Differences in intracellular drug accumulation between protease inhibitors. Khoo S, Hennessy M, Mulcahy F, Clarke S, Back DJ, Hoggard PG, Tjia J, Wilkins EGL, Carey P, Williams I, Peters B, Barry MG. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, February 2001, abstract 258.
	Quantification of d4T triphosphate (d4TTP) in ZDV naive and ZDV experienced HIV-infected individuals by an enzymatic assay. Phiboonbanakit D, Lloyd J, Khoo S, Wilkins E, Maher B, Barry M, Back D. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, February 2001, abstract 487.
	The effect of hydroxyurea (HU) on intracellular deoxy- and dideoxynucleoside triphosphate ratios in naive subjects receiving ZDV, ABC, 3TC± NVP over 48 weeks–CHARM phosphorylation substudy. Back D, Hoggard P, Maherbe A, Wood R, Kewn S, Sales S, Khoo S, De Vries S, Gould J. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, February 2001, abstract 747.
	Potential clinical relevance of drug transporters in antiretroviral pharmacology. Back D, Jones K, Hennessy M, Khoo S, Meaden R, Mulcahy F, Barry M. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, February 2001, abstract S3.

2000
	The Liverpool therapeutic drug monitoring service – a summary of the service and examples of use in clinical practice. Gibbons SE, Reynolds HE, Tjia JF, Khoo SH & Back DJ. abstract P259A, 5th International Congress on Drug Therapy in HIV Infection, Glasgow, October 2000. AIDS 2000;14(suppl 4);S89.
	Therapeutic drug monitoring in the management of subjects on the protease inhibitors nelfinavir and saquinavir: results of the Roche UK TDM service. Gibbons SE, Reynolds HE, Tjia JF, Khoo SH, Drake J & Back DJ. abstract P259, 5th International Congress on Drug Therapy in HIV Infection, Glasgow, October 2000. AIDS 2000;14(suppl 4);S89.
	Measurement of nucleoside analogue triphosphates by enzymatic assay in HIV patients in a clinical setting. Hoggard PG, Kewn S, Sales SD, Lloyd J, Maher B, Khoo SH, Wilkins EGL, Jones T, Pillay D, Sabin C & Back DJ. abstract PL8.4, 5th International Congress on Drug Therapy in HIV Infection, Glasgow, October 2000. AIDS 2000;14(suppl 4);S10.
	Role of P-gp and MRP in cellular influx/efflux of protease inhibitors in vitro. Jones K, Bray PG, Ward SA, Khoo SH, Davey RA & Back DJ. abstract P271, 5th International Congress on Drug Therapy in HIV Infection, Glasgow, October 2000. AIDS 2000;14(suppl 4);S93–94.
	Lipodystrophy in patients with HIV-1 infection: effect of stopping protease inhibitors on TNF-receptor levels, insulin resistance and lipid profile. Maher B, Lloyd J, Wilkins EGL, Fraser WD, Back DJ, Park BK & Pirmohamed M. abstract P137A, 5th International Congress on Drug Therapy in HIV Infection, Glasgow, October 2000. AIDS 2000;14(suppl 4);S56.
	Decreased P-glycoprotein but unaltered multidrug resistance-associated protein in HIV patients. Meaden ER, Brown RA, Hoggard PG, Maher B, Khoo SH & Back DJ. abstract P272, 5th International Congress on Drug Therapy in HIV Infection, Glasgow, October 2000. AIDS 2000;14(suppl 4);S94.
	The pharmacokinetics of abacavir phosphorylation in peripheral blood mononuclear cells from HIV+ patients. Kewn S, Maher B, Hoggard PG, Khoo SH, Carey P, Wilkins E, Gould J & Back DJ. abstract P276A, 5th International Congress on Drug Therapy in HIV Infection, Glasgow, October 2000. AIDS 2000;14(suppl 4);S95–96.
	The feasibility of therapeutic drug monitoring for protease inhibitors. Lloyd J, Maher B, Khoo S, Gibbons S & Back D. 6th Annual Conference of the British HIV Association, Edinburgh, March 2000, abstract P26.
	The relationship between antiretroviral drug levels, resistance, adherence and treatment failure in a routine clinical setting. Lloyd J, Sabin C, Jones T, Hoggard P, Wilkins E, Khoo S, Verbiest W, Hertogs K, Groen K, Pillay D, and Back D. 6th Annual Conference of the British HIV Association, Edinburgh, March 2000, abstract P25.
	Factors influencing the intracellular accumulation of protease inhibitors. Jones K, Hoggard PG, Sales SD, Khoo SH, Maher B, Lloyd J, Back DJ. First International Workshop on Clinical Pharmacology of HIV Infection, Noordwijk, March 2000.
	Quantification of nucleoside analogue triphosphates by enzymatic assay. Hoggard P, Sales S, Kewn S, Khoo S, Maher B, Lloyd J, Wilkins E, Back D. First International Workshop on Clinical Pharmacology of HIV Infection, Noordwijk, March 2000
	Cellular influx-efflux of protease inhibitors. Back D, Jones K, Maher B & Hoggard P. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2000, abstract 93.
	Therapeutic drug monitoring of protease inhibitors; what to measure and when. Merry C, Back DJ, Barry MG, Gibbons SE, Lloyd J, Khoo SH, Tjia JF, Reynolds H, Carey P & Mulcahy F. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2000, abstract 104.
	The pharmacokinetics of nelfinavir administered twice and three times daily to HIV-positive patients. Hennessy M, Clarke S, Merry C, Ryan M, Mulcahy F, Gibbons S, Back D. Br J Clin Pharmacol 2000;49(5):499.

1999
	The effect of grapefruit juice constituents on the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of saquinavir. Eagling VA, Profit L, Back DJ. Br J Clin Pharmacol 1999;47(5):593.
	Intracellular concentrations of the HIV protease inhibitors indinavir, ritonavir and saquinavir in vivo. Jones K, Hoggard PG, Back DJ. Br J Clin Pharmacol. 1999;48(6):880P–1P.
	Intracellular activation of lamivudine (3TC) and determination of 2'-deoxy-cytidine-5'-triphosphate (dCTP) in the presence and absence of various drugs in HepG2 cell. Kewn S, Hoggard PG, Sales SD, Back DJ. Br J Clin Pharmacol 1999;48(6):883P.
	The P-glycoprotein mediated transport of the HIV protease inhibitors saquinavir, ritonavir and indinavir in Caco-2 cells. Profit L & Back DJ Br J Clin Pharmacol. 1999;48(6):882P.
	The effect of P-glycoprotein on saquinavir absorption in Caco-2 cells. Profit L, Eagling VA, Back DJ. Br J Clin Pharmacol. 1999;47(5):594.
	Cytosolic zidovudine anabolites are responsible for cytotoxicity in isolated PBMCs. Sales SD, Hoggard PG, Hart CA & Back DJ. Br J Clin Pharmacol. 1999;48(6):881P–2P.

1998
	Zidovudine phosphorylation determined at intervals over 12 months in naive and antiretroviral experienced patients. Back DJ, Hoggard PG, Gibbons SE, Lloyd J, Khoo SH, Wilkins EG, Merry C, Barry MG, Dann L, Loveday C. 12th World AIDS Conference, Geneva, June/July 1998, abstract 42260.
	Enhanced activation of nucleoside analogues in the presence of hydroxyurea in vitro. Back DJ, Kewn S, Hoggard PG, Henry-Mowatt JS, Barry MG. 12th World AIDS Conference, Geneva, June/July 1998, abstract 42262.
	Control of zidovudine phosphorylation: the role of increasing thymidine kinase activity versus reduction of thymidine monophosphate levels. Back DJ, Phiboonbanakit D. 12th World AIDS Conference, Geneva, June/July 1998, abstract 42264.
	Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV infected patients. Merry C, Barry MG, Mulcahy F, Back DJ. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1998, abstract 352.
	The pharmacokinetics of nelfinavir alone and in combination with nevirapine. Merry C, Barry MG, Mulcahy F, Ryan M, Back DJ. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1998, abstract 351.
	Zidovudine (ZDV) phosphorylation determined at intervals over 12 months in naive and antiretroviral experienced HIV+ patients. Back DJ, Hoggard PG, Gibbons SE, Lloyd J, Khoo SH, Wilkins EG, Merry C, Barry MG. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1998, abstract LB10.
	Saquinavir absorption: Role of P-glycoprotein Back D, Eagling V, Profit L. AIDS 1998;12(S4):P53.

Last reviewed: 6 October 2009